This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Frank, G.J. Articles by Frank, G. J. Search for Related Content PubMed PubMed Citation Articles by Frank, G.J. Articles by Frank, G. J. Social Bookmarking                         What's this?

Overall Tolerance and Safety of Quinapril in Clinical Trials

ANN ARBOR, MICHIGAN, Cardiovascular Clinical Therapeutics Parke-Davis Pharmaceutical Research Division Warner-Lambert Company 2800 Plymouth Road Ann Arbor, Michigan 48105-2430

L.E. Knapp, Pharm.D.

ANN ARBOR, MICHIGAN, Cardiovascular Clinical Therapeutics Parke-Davis Pharmaceutical Research Division Warner-Lambert Company 2800 Plymouth Road Ann Arbor, Michigan 48105-2430

R.W. McLain, M.S.

Cardiovascular Clinical Therapeutics Parke-Davis Pharmaceutical Research Division Warner-Lambert Company 2800 Plymouth Road Ann Arbor, Michigan 48105-2430

Graham J. Frank, M. D.

Cardiovascular Clinical Therapeutics Parke-Davis Pharmaceutical Research Division Warner-Lambert Company 2800 Plymouth Road Ann Arbor, Michigan 48105-2430

A comprehensive analysis of the reporting of adverse events, with drawals due to adverse events, and serious adverse events has been con ducted on 2,010 patients treated with quinapril hydrochloride. An analysis of all events (from both double-blind and open label studies combined) showed no increase in the incidence of events reported in congestive heart failure (CHF) patients compared to hypertensive patients.

When the data for all studies were combined, an age analysis showed no increase in the total reporting of ad verse events in the 379 elderly pa tients studied. The incidence of events was lower in those patients who did not take concomitant di uretic therapy.

A comparison of the double-blind phases showed quinapril to have a lower incidence of adverse events than captopril, enalapril, or chlor thalidone. An analysis of the onset of events, or withrawals, did not show an increase with time on quinapril therapy, and no dose-relationship. A review of serious adverse events did not reveal an unexpected occurrence or a high incidence of serious events considered to be related to quinapril therapy. The proportion of patients who experienced "first-dose" hypo tension, or symptomatic hypotension was similar to captopril or enalapril. Quinapril, a nonsulfhydryl ACE inhibitor, has been extensively stud ied and is equally well tolerated in the young and elderly for the treatment of hypertension and CHF.

Angiology, Vol. 40, No. 4 part_2, 405-415 (1989)
DOI: 10.1177/000331978904000410


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. C. Olson, A. M. Horvath, B. M. Michniewicz, A. J. Sedman, W. A. Colburn, P. G. Welling, and S. C. Olson The Clinical Pharmacokinetics of Quinapril Angiology, January 1, 1989; 40(4_part_2): 351 - 359. [Abstract] [PDF]

				J. S. Banas JR. Preliminary Hemodynamic Report of the Efficacy and Safety of Quinapril in Acute and Chronic Treatment of Patients with Congestive Heart Failure Angiology, January 1, 1989; 40(4_part_2): 396 - 404. [Abstract] [PDF]